                         SEQUENCE LISTING

<110>  King's College London
 
<120>  COMPOSITION

<130>  P6131WO

<150>  GB 2006093.5
<151>  2020-04-24

<160>  141   

<170>  PatentIn version 3.5

<210>  1
<211>  209
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MOv18 IgE Light (L) Chain

<400>  1

Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile 
1               5                   10                  15      


Ser Cys Arg Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln 
            20                  25                  30          


Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg 
        35                  40                  45              


Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr 
    50                  55                  60                  


Asp Tyr Ser Leu Thr Ile Ile Asn Leu Glu Gln Glu Asp Ile Ala Ile 
65                  70                  75                  80  


Tyr Phe Cys Gln Gln Ser Ser Thr Ile Pro Arg Thr Phe Gly Gly Gly 
                85                  90                  95      


Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile 
            100                 105                 110         


Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val 
        115                 120                 125             


Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys 
    130                 135                 140                 


Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu 
145                 150                 155                 160 


Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu 
                165                 170                 175     


Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr 
            180                 185                 190         


His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu 
        195                 200                 205             


Cys 
    


<210>  2
<211>  549
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MOv18 IgE Heavy (H) Chain

<400>  2

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Asp Tyr Ile Phe Thr Asn Tyr 
            20                  25                  30          


Asp Ile Thr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asp Pro Arg Ser Gly Lys Ser Tyr Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ser Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Thr Met Tyr Tyr Tyr Gly Ser Ser Pro Pro Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Gln Ser Pro Ser 
        115                 120                 125             


Val Phe Pro Leu Thr Arg Cys Cys Lys Asn Ile Pro Ser Asn Ala Thr 
    130                 135                 140                 


Ser Val Thr Leu Gly Cys Leu Ala Thr Gly Tyr Phe Pro Glu Pro Val 
145                 150                 155                 160 


Met Val Thr Trp Asp Thr Gly Ser Leu Asn Gly Thr Thr Met Thr Leu 
                165                 170                 175     


Pro Ala Thr Thr Leu Thr Leu Ser Gly His Tyr Ala Thr Ile Ser Leu 
            180                 185                 190         


Leu Thr Val Ser Gly Ala Trp Ala Lys Gln Met Phe Thr Cys Arg Val 
        195                 200                 205             


Ala His Thr Pro Ser Ser Thr Asp Trp Val Asp Asn Lys Thr Phe Ser 
    210                 215                 220                 


Val Cys Ser Arg Asp Phe Thr Pro Pro Thr Val Lys Ile Leu Gln Ser 
225                 230                 235                 240 


Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr Ile Gln Leu Leu Cys 
                245                 250                 255     


Leu Val Ser Gly Tyr Thr Pro Gly Thr Ile Asn Ile Thr Trp Leu Glu 
            260                 265                 270         


Asp Gly Gln Val Met Asp Val Asp Leu Ser Thr Ala Ser Thr Thr Gln 
        275                 280                 285             


Glu Gly Glu Leu Ala Ser Thr Gln Ser Glu Leu Thr Leu Ser Gln Lys 
    290                 295                 300                 


His Trp Leu Ser Asp Arg Thr Tyr Thr Cys Gln Val Thr Tyr Gln Gly 
305                 310                 315                 320 


His Thr Phe Glu Asp Ser Thr Lys Lys Cys Ala Asp Ser Asn Pro Arg 
                325                 330                 335     


Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile 
            340                 345                 350         


Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser 
        355                 360                 365             


Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val 
    370                 375                 380                 


Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr 
385                 390                 395                 400 


Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu 
                405                 410                 415     


Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met 
            420                 425                 430         


Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr 
        435                 440                 445             


Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu 
    450                 455                 460                 


Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp 
465                 470                 475                 480 


Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln 
                485                 490                 495     


Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu 
            500                 505                 510         


Val Thr Arg Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys Arg Ala 
        515                 520                 525             


Val His Glu Ala Ala Ser Pro Ser Gln Thr Val Gln Arg Ala Val Ser 
    530                 535                 540                 


Val Asn Pro Gly Lys 
545                 


<210>  3
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MOv18 IgE Light Chain Variable Domain

<400>  3

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asn Asn Phe 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ile Asn Leu Glu Gln 
65                  70                  75                  80  


Glu Asp Ile Ala Ile Tyr Phe Cys Gln Gln Ser Ser Thr Ile Pro Arg 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  4
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MOv18 IgE Heavy Chain Variable Domain

<400>  4

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Asp Tyr Ile Phe Thr Asn Tyr 
            20                  25                  30          


Asp Ile Thr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asp Pro Arg Ser Gly Lys Ser Tyr Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ser Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Thr Met Tyr Tyr Tyr Gly Ser Ser Pro Pro Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  5
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Palivizumab CDR H1

<400>  5

Gly Phe Ser Leu Ser Thr Ser Gly Met Ser Val Gly 
1               5                   10          


<210>  6
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Palivizumab CDR H2

<400>  6

Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser Leu Lys Ser 
1               5                   10                  15      


<210>  7
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Palivizumab CDR H3

<400>  7

Ser Met Ile Thr Asn Trp Tyr Phe Asp Val 
1               5                   10  


<210>  8
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Palivizumab CDR L1

<400>  8

Lys Cys Gln Leu Ser Val Gly Tyr Met His 
1               5                   10  


<210>  9
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Palivizumab CDR L2

<400>  9

Asp Thr Ser Lys Leu Ala Ser 
1               5           


<210>  10
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Palivizumab CDR L3

<400>  10

Phe Gln Gly Ser Gly Tyr Pro Phe Thr 
1               5                   


<210>  11
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ranibizumab CDR H1

<400>  11

Gly Tyr Asp Phe Thr His Tyr Gly Met Asn 
1               5                   10  


<210>  12
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ranibizumab CDR H2

<400>  12

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys 
1               5                   10                  15      


Arg 
    


<210>  13
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ranibizumab CDR H3

<400>  13

Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Phe Asp Val 
1               5                   10              


<210>  14
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  L1

<400>  14

Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 
1               5                   10      


<210>  15
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ranibizumab CDR L2

<400>  15

Phe Thr Ser Ser Leu His Ser 
1               5           


<210>  16
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ranibizumab CDR L3

<400>  16

Gln Gln Tyr Ser Thr Val Pro Trp Thr 
1               5                   


<210>  17
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HMW-MAA CDR H1

<400>  17

Gly Phe Thr Phe Ser Asn Tyr Trp 
1               5               


<210>  18
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HMW-MAA CDR H2

<400>  18

Ile Arg Leu Lys Ser Asn Asn Phe Gly Arg 
1               5                   10  


<210>  19
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HMW-MAA CDR H3

<400>  19

Thr Ser Tyr Gly Asn Tyr Val Gly His Tyr Phe Asp His 
1               5                   10              


<210>  20
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HMW-MAA CDR L1

<400>  20

Gln Asn Val Asp Thr Asn 
1               5       


<210>  21
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HMW-MAA CDR L2

<400>  21

Ser Ala Ser 
1           


<210>  22
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HMW-MAA CDR L3

<400>  22

Gln Gln Tyr Asn Ser Tyr Pro Leu Thr 
1               5                   


<210>  23
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HMW-MAA Variable Domain (Heavy Chain)

<400>  23

Glu Gln Val Lys Leu Gln Gln Ser Gly Gly Gly Leu Val Gln Pro Gly 
1               5                   10                  15      


Gly Ser Met Lys Leu Ser Cys Val Val Ser Gly Phe Thr Phe Ser Asn 
            20                  25                  30          


Tyr Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Ala Glu Ile Arg Leu Lys Ser Asn Asn Phe Gly Arg Tyr Tyr Ala 
    50                  55                  60                  


Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser 
65                  70                  75                  80  


Ser Ala Tyr Leu Gln Met Ile Asn Leu Arg Ala Glu Asp Thr Gly Ile 
                85                  90                  95      


Tyr Tyr Cys Thr Ser Tyr Gly Asn Tyr Val Gly His Tyr Phe Asp His 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  24
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HMW-MAA Alternative Variable Domain (Heavy Chain)

<400>  24

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Gly Glu Ile Arg Leu Lys Ser Asn Asn Phe Gly Arg Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 
65                  70                  75                  80  


Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Thr Ser Tyr Gly Asn Tyr Val Gly His Tyr Phe Asp His Trp 
            100                 105                 110         


Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120         


<210>  25
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HMW-MAA Variable Domain (Light Chain)

<400>  25

Asp Ile Glu Leu Thr Gln Ser Pro Lys Phe Met Ser Thr Ser Val Cys 
1               5                   10                  15      


Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Glu Pro Leu Leu 
        35                  40                  45              


Phe Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  26
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HMW-MAA Alternative Variable Domain (Light Chain)

<400>  26

Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Pro Leu Leu 
        35                  40                  45              


Phe Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  27
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Alemtuzumab CDR H1

<400>  27

Gly Phe Thr Phe Thr Asp Phe Tyr 
1               5               


<210>  28
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Alemtuzumab CDR H2

<400>  28

Ile Arg Asp Lys Ala Lys Gly Tyr Thr Thr 
1               5                   10  


<210>  29
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Alemtuzumab CDR H3

<400>  29

Ala Arg Glu Gly His Thr Ala Ala Pro Phe Asp Tyr 
1               5                   10          


<210>  30
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Alemtuzumab CDR L1

<400>  30

Gln Asn Ile Asp Lys Tyr 
1               5       


<210>  31
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Alemtuzumab CDR L2

<400>  31

Asn Thr Asn 
1           


<210>  32
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Alemtuzumab CDR L3

<400>  32

Leu Gln His Ile Ser Arg Pro Arg Thr 
1               5                   


<210>  33
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Atezolizumab CDR H1

<400>  33

Asp Ser Trp Ile His 
1               5   


<210>  34
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Atezolizumab CDR H2

<400>  34

Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr 
1               5                   10  


<210>  35
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Atezolizumab CDR H3

<400>  35

Arg His Trp Pro Gly Gly Phe 
1               5           


<210>  36
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Atezolizumab CDR L1

<400>  36

Asp Val Ser Thr Ala Val Ala 
1               5           


<210>  37
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Atezolizumab CDR L2

<400>  37

Ser Ala Ser Phe Leu Tyr 
1               5       


<210>  38
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Atezolizumab CDR L3

<400>  38

Gln Gln Tyr Leu Tyr His Pro Ala Thr 
1               5                   


<210>  39
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Avelumab CDR H1

<400>  39

Ser Tyr Ile Met Met 
1               5   


<210>  40
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Avelumab CDR H2

<400>  40

Ser Ile Tyr Pro Ser Gly Gly Ile Thr Phe 
1               5                   10  


<210>  41
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Avelumab CDR H3

<400>  41

Ile Lys Leu Phe Thr Val Thr Thr Val 
1               5                   


<210>  42
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Avelumab CDR L1

<400>  42

Val Gly Gly Tyr Asn Tyr Val Ser 
1               5               


<210>  43
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Avelumab CDR L2

<400>  43

Asp Val Ser Asn Arg Pro 
1               5       


<210>  44
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Avelumab CDR L2

<400>  44

Asp Val Ser Asn Arg Pro 
1               5       


<210>  45
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Avelumab CDR L3

<400>  45

Ser Ser Tyr Thr Ser Ser Ser Thr Arg Val 
1               5                   10  


<210>  46
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Bevacizumab CDR H1

<400>  46

Gly Tyr Thr Phe Thr Asn Tyr Gly 
1               5               


<210>  47
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Bevacizumab CDR H2

<400>  47

Ile Asn Thr Tyr Thr Gly Glu Pro 
1               5               


<210>  48
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Bevacizumab CDR H3

<400>  48

Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 
1               5                   10                  15      


<210>  49
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Bevacizumab CDR L1

<400>  49

Gln Asp Ile Ser Asn Tyr 
1               5       


<210>  50
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Bevacizumab CDR L2

<400>  50

Phe Thr Ser 
1           


<210>  51
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Bevacizumab CDR L3

<400>  51

Gln Gln Tyr Ser Thr Val Pro Trp Thr 
1               5                   


<210>  52
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Certolizumab CDR H1

<400>  52

Gly Tyr Val Phe Thr Asp Tyr Gly Met Asn 
1               5                   10  


<210>  53
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Certolizumab CDR H2

<400>  53

Gly Trp Ile Asn Thr Tyr Ile Gly Glu Pro Ile Tyr Ala Asp Ser Val 
1               5                   10                  15      


Lys Gly 
        


<210>  54
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Certolizumab CDR H3

<400>  54

Ala Arg Gly Tyr Arg Ser Tyr Ala Met Asp Tyr 
1               5                   10      


<210>  55
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Certolizumab CDR L1

<400>  55

Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala 
1               5                   10      


<210>  56
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Certolizumab CDR L2

<400>  56

Ser Ala Ser Phe Leu Tyr 
1               5       


<210>  57
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Certolizumab CDR L3

<400>  57

Gln Gln Tyr Asn Ile Tyr Pro Leu 
1               5               


<210>  58
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cetuximab CDR H1

<400>  58

Gly Phe Ser Leu Thr Asn Tyr Gly 
1               5               


<210>  59
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cetuximab CDR H2

<400>  59

Ile Trp Ser Gly Gly Asn Thr 
1               5           


<210>  60
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cetuximab CDR H3

<400>  60

Ala Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr 
1               5                   10              


<210>  61
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cetuximab CDR L1

<400>  61

Gln Ser Ile Gly Thr Asn 
1               5       


<210>  62
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cetuximab CDR L2

<400>  62

Tyr Ala Ser 
1           


<210>  63
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cetuximab CDR L3

<400>  63

Gln Gln Asn Asn Asn Trp Pro Thr Thr 
1               5                   


<210>  64
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Durvalumab CDR H1

<400>  64

Arg Tyr Trp Met Ser 
1               5   


<210>  65
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Durvalumab CDR H2

<400>  65

Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr 
1               5                   10  


<210>  66
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Durvalumab CDR H3

<400>  66

Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe 
1               5                   10  


<210>  67
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Durvalumab CDR L1

<400>  67

Arg Val Ser Ser Ser Tyr Leu Ala 
1               5               


<210>  68
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Durvalumab CDR L2

<400>  68

Asp Ala Ser Ser Arg Ala 
1               5       


<210>  69
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Durvalumab CDR L3

<400>  69

Gln Gln Tyr Gly Ser Leu Pro Trp Thr 
1               5                   


<210>  70
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Efalizumab CDR H1

<400>  70

Gly Tyr Ser Phe Thr Gly His Trp Met Asn 
1               5                   10  


<210>  71
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Efalizumab CDR H2

<400>  71

Gly Ile Met Ile His Pro Ser Asp Ser Glu Thr Arg Tyr Asn Gln Lys 
1               5                   10                  15      


Phe Lys Asp Ile 
            20  


<210>  72
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Efalizumab CDR H3

<400>  72

Ala Arg Ile Gly Ile Tyr Phe Tyr Gly Thr Thr Tyr Phe Asp Tyr Ile 
1               5                   10                  15      


<210>  73
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Efalizumab CDR L1

<400>  73

Arg Ala Ser Lys Thr Ile Ser Lys Tyr Leu Ala 
1               5                   10      


<210>  74
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Efalizumab CDR L2

<400>  74

Ser Gly Ser Thr Leu Gln 
1               5       


<210>  75
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Efalizumab CDR L3

<400>  75

Gln Gln His Asn Glu Tyr Pro Leu 
1               5               


<210>  76
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Omalizumab CDR H1

<400>  76

Gly Tyr Ser Ile Thr Ser Gly Tyr Ser Trp Asn 
1               5                   10      


<210>  77
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Omalizumab CDR H2

<400>  77

Ala Ser Ile Thr Tyr Asp Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  78
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Omalizumab CDR H3

<400>  78

Ala Arg Gly Ser His Tyr Phe Gly His Trp His Phe Ala Val 
1               5                   10                  


<210>  79
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Omalizumab CDR L1

<400>  79

Arg Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Met Asn 
1               5                   10                  15  


<210>  80
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Omalizumab CDR L2

<400>  80

Ala Ala Ser Tyr Leu Glu 
1               5       


<210>  81
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Omalizumab CDR L3

<400>  81

Gln Gln Ser His Glu Asp Pro Tyr 
1               5               


<210>  82
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Panitumumab CDR H1

<400>  82

Gly Gly Ser Val Ser Ser Gly Asp Tyr Tyr 
1               5                   10  


<210>  83
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Panitumumab CDR H2

<400>  83

Ile Tyr Tyr Ser Gly Asn Thr 
1               5           


<210>  84
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Panitumumab CDR H3

<400>  84

Val Arg Asp Arg Val Thr Gly Ala Phe Asp Ile 
1               5                   10      


<210>  85
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Panitumumab CDR L1

<400>  85

Gln Asp Ile Ser Asn Tyr 
1               5       


<210>  86
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Panitumumab CDR L2

<400>  86

Asp Ala Ser 
1           


<210>  87
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Panitumumab CDR L3

<400>  87

Gln His Phe Asp His Leu Pro Leu Ala 
1               5                   


<210>  88
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pertuzumab CDR L1

<400>  88

Gly Phe Thr Phe Thr Asp Tyr Thr 
1               5               


<210>  89
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pertuzumab CDR H2

<400>  89

Val Asn Pro Asn Ser Gly Gly Ser 
1               5               


<210>  90
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pertuzumab CDR H3

<400>  90

Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr 
1               5                   10          


<210>  91
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pertuzumab CDR L1

<400>  91

Gln Asp Val Ser Ile Gly 
1               5       


<210>  92
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pertuzumab CDR L2

<400>  92

Ser Ala Ser 
1           


<210>  93
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Pertuzumab CDR L3

<400>  93

Gln Gln Tyr Tyr Ile Tyr Pro Tyr Thr 
1               5                   


<210>  94
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Rituximab CDR H1

<400>  94

Gly Tyr Thr Phe Thr Ser Tyr Asn 
1               5               


<210>  95
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Rituximab CDR H2

<400>  95

Ile Tyr Pro Gly Asn Gly Asp Thr 
1               5               


<210>  96
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Rituximab CDR H3

<400>  96

Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Phe Asn Val 
1               5                   10              


<210>  97
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Rituximab CDR L1

<400>  97

Ser Ser Val Ser Tyr 
1               5   


<210>  98
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Rituximab CDR L2

<400>  98

Ala Thr Ser 
1           


<210>  99
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Rituximab CDR L3

<400>  99

Gln Gln Trp Thr Ser Asn Pro Pro Thr 
1               5                   


<210>  100
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Trastuzumab CDR H1

<400>  100

Gly Phe Asn Ile Lys Asp Thr Tyr 
1               5               


<210>  101
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Trastuzumab CDR H2

<400>  101

Ile Tyr Pro Thr Asn Gly Tyr Thr 
1               5               


<210>  102
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Trastuzumab CDR H3

<400>  102

Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr 
1               5                   10              


<210>  103
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Trastuzumab CDR L1

<400>  103

Gln Asp Val Asn Thr Ala 
1               5       


<210>  104
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Trastuzumab CDR L2

<400>  104

Ser Ala Ser 
1           


<210>  105
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  L3

<400>  105

Gln Gln His Tyr Thr Thr Pro Pro Thr 
1               5                   


<210>  106
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Adalimumab CDR H1

<400>  106

Asp Tyr Ala Met His 
1               5   


<210>  107
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Adalimumab CDR H2

<400>  107

Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val Glu 
1               5                   10                  15      


Gly 
    


<210>  108
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Adalimumab CDR H3

<400>  108

Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr 
1               5                   10          


<210>  109
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Adalimumab CDR L1

<400>  109

Arg Ala Ser Gln Gly Ile Arg Asn Tyr Leu Ala 
1               5                   10      


<210>  110
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Adalimumab CDR L2

<400>  110

Ala Ala Ser Thr Leu Gln Ser 
1               5           


<210>  111
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Adalimumab CDR L3

<400>  111

Gln Arg Tyr Asn Arg Ala Pro Tyr Thr 
1               5                   


<210>  112
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Basiliximab CDR H1

<400>  112

Gly Tyr Ser Phe Thr Arg Tyr Trp Met His 
1               5                   10  


<210>  113
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Basiliximab CDR H2

<400>  113

Ala Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Gln Lys Phe Glu 
1               5                   10                  15      


Gly 
    


<210>  114
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Basiliximab CDR H3

<400>  114

Asp Tyr Gly Tyr Tyr Phe Asp Phe 
1               5               


<210>  115
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Basiliximab CDR L1

<400>  115

Ser Ala Ser Ser Ser Arg Ser Tyr Met Gln 
1               5                   10  


<210>  116
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Basiliximab CDR L2

<400>  116

Asp Thr Ser Lys Leu Ala Ser 
1               5           


<210>  117
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Basiliximab CDR L3

<400>  117

His Gln Arg Ser Ser Tyr Thr 
1               5           


<210>  118
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Belimumab CDR H1

<400>  118

Gly Gly Thr Phe Asn Asn Asn Ala Ile Asn 
1               5                   10  


<210>  119
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Belimumab CDR H2

<400>  119

Gly Ile Ile Pro Met Phe Gly Thr Ala Lys Tyr Ser Gln Asn Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  120
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Belimumab CDR H3

<400>  120

Ser Arg Asp Leu Leu Leu Phe Pro His His Ala Leu Ser Pro 
1               5                   10                  


<210>  121
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Belimumab CDR L1

<400>  121

Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Ser 
1               5                   10      


<210>  122
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Belimumab CDR L2

<400>  122

Gly Lys Asn Asn Arg Pro Ser 
1               5           


<210>  123
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Belimumab CDR L3

<400>  123

Ser Ser Arg Asp Ser Ser Gly Asn His Trp Val 
1               5                   10      


<210>  124
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Daclizumab CDR H1

<400>  124

Gly Tyr Thr Phe Thr Ser Tyr Arg Met His 
1               5                   10  


<210>  125
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Daclizumab CDR H2

<400>  125

Tyr Ile Asn Pro Ser Thr Gly Tyr Thr Glu Tyr Asn Gln Lys Phe Lys 
1               5                   10                  15      


Asp 
    


<210>  126
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Daclizumab CDR H3

<400>  126

Gly Gly Gly Val Phe Asp Tyr 
1               5           


<210>  127
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Daclizumab CDR L1

<400>  127

Ser Ala Ser Ser Ser Ile Ser Tyr Met His 
1               5                   10  


<210>  128
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Daclizumab CDR L2

<400>  128

Thr Thr Ser Asn Leu Ala Ser 
1               5           


<210>  129
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Daclizumab CDR L3

<400>  129

His Gln Arg Ser Thr Tyr Pro Leu Thr 
1               5                   


<210>  130
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Infliximab CDR H1

<400>  130

Ile Phe Ser Asn His Trp 
1               5       


<210>  131
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Infliximab CDR H2

<400>  131

Arg Ser Lys Ser Ile Asn Ser Ala Thr His 
1               5                   10  


<210>  132
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Infliximab CDR H3

<400>  132

Asn Tyr Tyr Gly Ser Thr Tyr 
1               5           


<210>  133
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Infliximab CDR L1

<400>  133

Phe Val Gly Ser Ser Ile His 
1               5           


<210>  134
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Infliximab CDR L2

<400>  134

Lys Tyr Ala Ser Glu Ser Met 
1               5           


<210>  135
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Infliximab CDR L3

<400>  135

Gln Ser His Ser Trp 
1               5   


<210>  136
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Natalizumab CDR H1

<400>  136

Gly Phe Asn Ile Lys Asp Thr Tyr Ile His 
1               5                   10  


<210>  137
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Natalizumab CDR H2

<400>  137

Arg Ile Asp Pro Ala Asn Gly Tyr Thr Lys Tyr Asp Pro Lys Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  138
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Natalizumab CDR H3

<400>  138

Glu Gly Tyr Tyr Gly Asn Tyr Gly Val Tyr Ala Met Asp Tyr 
1               5                   10                  


<210>  139
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Natalizumab CDR L1

<400>  139

Lys Thr Ser Gln Asp Ile Asn Lys Tyr Met Ala 
1               5                   10      


<210>  140
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Natalizumab CDR L2

<400>  140

Tyr Thr Ser Ala Leu Gln Pro 
1               5           


<210>  141
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Natalizumab CDR L3

<400>  141

Leu Gln Tyr Asp Asn Leu Trp Thr 
1               5               


